These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
755 related articles for article (PubMed ID: 1485180)
21. Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers. Farley PA; Dempsey CL; Shillington AA; Kulis-Robitaille C; Colgan K; Bernstein G Am J Health Syst Pharm; 1997 Nov; 54(21):2478-82. PubMed ID: 9359954 [TBL] [Abstract][Full Text] [Related]
22. Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy. DiBenedetto J; Cubeddu LX; Ryan T; Kish JA; Sciortino D; Beall C; Eisenberg PD; Henderson C; Griffin D; Wentz A Clin Ther; 1995; 17(6):1091-8. PubMed ID: 8750400 [TBL] [Abstract][Full Text] [Related]
23. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy. Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140 [TBL] [Abstract][Full Text] [Related]
24. Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen. Hesketh PJ; Beck T; Uhlenhopp M; Kris MG; Hainsworth JD; Harker WG; Cohen JR; Lester E; Kessler JF; Griffen D J Clin Oncol; 1995 Aug; 13(8):2117-22. PubMed ID: 7636556 [TBL] [Abstract][Full Text] [Related]
25. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713 [TBL] [Abstract][Full Text] [Related]
26. Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. Alvarez O; Freeman A; Bedros A; Call SK; Volsch J; Kalbermatter O; Halverson J; Convy L; Cook L; Mick K J Pediatr Hematol Oncol; 1995 May; 17(2):145-50. PubMed ID: 7749764 [TBL] [Abstract][Full Text] [Related]
27. Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy. Treish I; Shord S; Valgus J; Harvey D; Nagy J; Stegal J; Lindley C Support Care Cancer; 2003 Aug; 11(8):516-21. PubMed ID: 12836088 [TBL] [Abstract][Full Text] [Related]
28. Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy. Plosker GL; Milne RJ Pharmacoeconomics; 1992 Oct; 2(4):285-304. PubMed ID: 10147044 [TBL] [Abstract][Full Text] [Related]
29. Acute and delayed nausea and emesis control in pediatric oncology patients. Holdsworth MT; Raisch DW; Frost J Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398 [TBL] [Abstract][Full Text] [Related]
31. Antiemetic prophylaxis with ondansetron and methylprednisolone vs metoclopramide and methylprednisolone in mild and moderately emetogenic chemotherapy. Tsavaris NB; Koufos C; Katsikas M; Dimitrakopoulos A; Athanasiou E; Linardaki G J Pain Symptom Manage; 1999 Sep; 18(3):218-22. PubMed ID: 10517044 [TBL] [Abstract][Full Text] [Related]
32. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK). Joss RA; Bacchi M; Buser K; Kirchner V; Neuenschwander H; Orth B; Aapro MS; Thürlimann B Ann Oncol; 1994 Mar; 5(3):253-8. PubMed ID: 8186174 [TBL] [Abstract][Full Text] [Related]
33. Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. Sigsgaard T; Herrstedt J; Handberg J; Kjaer M; Dombernowsky P J Clin Oncol; 2001 Apr; 19(7):2091-7. PubMed ID: 11283143 [TBL] [Abstract][Full Text] [Related]
34. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486 [TBL] [Abstract][Full Text] [Related]
35. Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron. Holdsworth MT; Raisch DW; Winter SS; Chavez CM Support Care Cancer; 1998 Mar; 6(2):132-8. PubMed ID: 9540172 [TBL] [Abstract][Full Text] [Related]
36. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739 [TBL] [Abstract][Full Text] [Related]
38. [Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study]. Serve H; Perker M; Ertl A; Reichold M; Fink U; Berdel WE Onkologie; 1990 Oct; 13(5):369-74. PubMed ID: 2150552 [TBL] [Abstract][Full Text] [Related]
39. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. Herrstedt J; Sigsgaard T; Boesgaard M; Jensen TP; Dombernowsky P N Engl J Med; 1993 Apr; 328(15):1076-80. PubMed ID: 8455664 [TBL] [Abstract][Full Text] [Related]
40. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy. Bhatia A; Tripathi KD; Sharma M Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]